The Binding of Palonosetron and Other Antiemetic Drugs to the Serotonin 5-HT3 Receptor.
5-HT3
Cryo-EM
antiemetics
nausea
receptor
serotonin
vomiting
Journal
Structure (London, England : 1993)
ISSN: 1878-4186
Titre abrégé: Structure
Pays: United States
ID NLM: 101087697
Informations de publication
Date de publication:
06 10 2020
06 10 2020
Historique:
received:
24
03
2020
revised:
18
06
2020
accepted:
08
07
2020
pubmed:
30
7
2020
medline:
14
8
2021
entrez:
30
7
2020
Statut:
ppublish
Résumé
Inaccurately perceived as niche drugs, antiemetics are key elements of cancer treatment alleviating the most dreaded side effect of chemotherapy. Serotonin 5-HT3 receptor antagonists are the most commonly prescribed class of drugs to control chemotherapy-induced nausea and vomiting. These antagonists have been clinically successful drugs since the 1980s, yet our understanding of how they operate at the molecular level has been hampered by the difficulty of obtaining structures of drug-receptor complexes. Here, we report the cryoelectron microscopy structure of the palonosetron-bound 5-HT3 receptor. We investigate the binding of palonosetron, granisetron, dolasetron, ondansetron, and cilansetron using molecular dynamics, covering the whole set of antagonists used in clinical practice. The structural and computational results yield detailed atomic insight into the binding modes of the drugs. In light of our data, we establish a comprehensive framework underlying the inhibition mechanism by the -setron drug family.
Identifiants
pubmed: 32726573
pii: S0969-2126(20)30237-9
doi: 10.1016/j.str.2020.07.004
pii:
doi:
Substances chimiques
Antiemetics
0
Receptors, Serotonin, 5-HT3
0
Serotonin 5-HT3 Receptor Antagonists
0
Serotonin
333DO1RDJY
Palonosetron
5D06587D6R
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1131-1140.e4Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests The authors declare no competing interests.